Nanologica AB (DE:4YD)
FRANKFURT:4YD
4YD Stock Chart & Stats
€0.04
<€0.01(1.49%)
At close: 4:00 PM EST
€0.04
<€0.01(1.49%)
Day’s Range― - ―
52-Week Range€0.03 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€9.53M
Enterprise Value€49.33M
Total Cash (Recent Filing)€3.55M
Total Debt (Recent Filing)€21.68M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding294,524,100
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€7.79M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Product DemandNanologica’s core business supplies silica separation media to pharmaceutical workflows where products act as consumables. That creates recurring purchase patterns and durable demand from drug development and manufacturing customers, supporting steady revenue potential if product fit persists.
Top-line Growth / Commercial TractionRevenue climbed materially year-over-year, signaling strengthening commercial adoption of its silica products. Sustained revenue growth over multiple quarters would validate product-market fit and can support operating leverage over time if gross margins are improved and customer repeat rates hold.
Manageable Reported LeverageReported debt levels are not extreme relative to equity, providing some financial flexibility versus highly leveraged peers. Manageable leverage can allow continued investment in commercialization or R&D over the medium term, assuming access to capital markets or operational improvement.
Bears Say
Negative Gross ProfitA structurally negative gross profit indicates the company’s product revenues do not cover direct costs, a core profitability issue. Unless manufacturing costs, pricing, or product mix change materially, negative gross margins impede any path to sustainable operating profit and long-term viability.
Sustained Cash BurnPersistent negative operating and free cash flow forces reliance on external financing to fund operations. Continued cash consumption increases dilution or refinancing risk and limits the company’s ability to invest in scaling or margin improvement without addressing core profitability drivers.
Sharply Reduced Equity BaseA steep decline in equity weakens the balance-sheet cushion against losses and raises the likelihood of future capital raises. Lower capitalization reduces strategic flexibility and heightens financing risk if operating improvements are slower than expected, leading to potential dilution.
Nanologica AB News
4YD FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was €0.03 and its highest was €0.15 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is €9.53M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is May 20, 2026 which is in 55 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Feb 26, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of -€0.009 by -€0.008.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 294,524,100 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -€0.017 in its last earnings report, missing expectations of -€0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in DE:4YD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―